Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms.

Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7608025 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2072 (Electronic) Linking ISSN: 00333158 NLM ISO Abbreviation: Psychopharmacology (Berl) Subsets: MEDLINE

Original Publication: Berlin, New York, Springer-Verlag.

Psilocybin*/administration & dosage ; Psilocybin*/pharmacology ; Selective Serotonin Reuptake Inhibitors*/administration & dosage ; Selective Serotonin Reuptake Inhibitors*/pharmacology ; Hallucinogens*/administration & dosage ; Hallucinogens*/pharmacology ; Agaricales* ; Drug Interactions*; Humans

Rationale: Treatments with the serotonergic psychedelic psilocybin are being investigated for multiple neuropsychiatric disorders. Because many patients with these disorders use selective serotonin reuptake inhibitors (SSRIs), understanding interactions between psilocybin and SSRIs is critical for evaluating the safety, efficacy, and scalability of psilocybin-based treatments. Current knowledge about these interactions is limited, as most clinical psilocybin research has prohibited concomittant SSRI use.
Objectives: We aimed to explore potential interactions between psilocybin and SSRIs by characterizing peoples' real-world experiences using psilocybin mushrooms and SSRIs together.
Methods: We conducted a systematic search of Reddit for posts describing psilocybin mushroom and SSRI coadministration. We identified 443 eligible posts and applied qualitative content analysis to each.
Results: 8% of posts reported negative physical or psychological effects resulting from coadministration. These included 13 reports that may reflect serotonin toxicity, and 1 concerning for a psychotic/manic episode. 54% of posts described reduced intensity of the acute psilocybin experience, but 39% reported unchanged intensity with SSRI coadministration.
Conclusions: Psilocybin's interactions with SSRIs are likely complex and may depend on multiple factors. Prospective studies are needed to evaluate whether psilocybin treatments are reliably safe and effective in the setting of SSRI use.
(© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.)

Abadie D, Rousseau V, Logerot S et al (2015) Serotonin syndrome: analysis of cases registered in the French pharmacovigilance database. J Clin Psychopharmacol 35(4):382. (PMID: 2608297310.1097/JCP.0000000000000344)
Aday JS, Davis AK, Mitzkovitz CM et al (2021) Predicting reactions to psychedelic drugs: a systematic review of states and traits related to acute drug effects. ACS Pharmacol Transl Sci 4(2):424–435 (American Chemical Society). (PMID: 33860172803377310.1021/acsptsci.1c00014)
Aday JS, Heifets BD, Pratscher SD et al (2022) Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology. https://doi.org/10.1007/s00213-022-06123-7. (PMID: 10.1007/s00213-022-06123-73535915910184717)
Alvarez E, Perez V, Artigas F (2014) Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 10:1297–1307. (PMID: 25075188410697110.2147/NDT.S41387)
Anderson BT, Danforth A, Daroff PR et al (2020) Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine 27:100538 (Elsevier). (PMID: 33150319759929710.1016/j.eclinm.2020.100538)
Artigas F, Romero L, De Montigny C et al (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19(9):378–383. (PMID: 887335210.1016/S0166-2236(96)10037-0)
Auxier B, Anderson M (2021) Social media use in 2021. https://www.pewresearch.org/internet/2021/04/07/social-media-use-in-2021/ . Accessed 25 July 2023.
Bahri S, Mnie-Filali O, Dkhissi-Benyahya O et al (2014) Neuroadaptations of the 5-HT system induced by antidepressant treatments: old and new strategies. Addict Addict Disord 1:1–11. (PMID: 10.24966/AAD-7276/100001)
Barber G, Nemeroff CB, Siegel S (2022) A case of prolonged mania, psychosis, and severe depression after psilocybin use: implications of increased psychedelic drug availability. Am J Psychiatry 179(12):892–896. (PMID: 3645303710.1176/appi.ajp.22010073)
Barnhart WJ, Makela EH, Latocha MJ (2004) SSRI-induced apathy syndrome: a clinical review. J Psychiatr Pract 10(3):196–199. (PMID: 1533022810.1097/00131746-200405000-00010)
Beasley CM, Masica DN, Potvin JH (1992) Fluoxetine: a review of receptor and functional effects and their clinical implications. Psychopharmacology 107(1):1–10. (PMID: 131703810.1007/BF02244958)
Becker AM, Holze F, Grandinetti T et al (2022) Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clin Pharmacol Ther 111(4):886–895. (PMID: 3474331910.1002/cpt.2487)
Bhagwagar Z, Hinz R, Taylor M et al (2006) Increased 5-HT 2A receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [11 C]MDL 100,907. Am J Psychiatry 163(9):1580–1587. (PMID: 1694618410.1176/ajp.2006.163.9.1580)
Bickel M, Ditting T, Watz H et al (2005) Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after ‘magic mushroom’ abuse. Eur J Emerg Med 12(6):306–308. (PMID: 1627626210.1097/00063110-200512000-00011)
Blond BN, Schindler EAD (2023) Case report: Psychedelic-induced seizures captured by intracranial electrocorticography. Front Neurol 14:1214969. (PMID: 374566531034343310.3389/fneur.2023.1214969)
Blough BE, Landavazo A, Decker AM et al (2014) Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes. Psychopharmacology 231(21):4135–4144. (PMID: 24800892419423410.1007/s00213-014-3557-7)
Bogenschutz MP, Forcehimes AA, Pommy JA et al (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29(3):289–299. (PMID: 2558639610.1177/0269881114565144)
Bogenschutz MP, Ross S, Bhatt S et al (2022) Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 79(10):953–962. (PMID: 36001306940385410.1001/jamapsychiatry.2022.2096)
Bonson KR, Buckholtz JW, Murphy DL (1996) Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology: Off Publ Am Coll Neuropsychopharmacol 14(6):425–436. (PMID: 10.1016/0893-133X(95)00145-4)
Borowiak KS, Ciechanowski K, Waloszczyk P (1998) Psilocybin mushroom (Psilocybe semilanceata) intoxication with myocardial infarction. J Toxicol Clin Toxicol 36(1–2):47–49. (PMID: 954104210.3109/15563659809162584)
Boyer EW, Shannon M (2005) The serotonin syndrome. N Engl J Med 352(11):1112–1120 (Massachusetts Medical Society). (PMID: 1578466410.1056/NEJMra041867)
Breeksema JJ, Niemeijer AR, Krediet E et al (2020) Psychedelic treatments for psychiatric disorders: a systematic review and thematic synthesis of patient experiences in qualitative studies. CNS Drugs 34(9):925–946. (PMID: 32803732744767910.1007/s40263-020-00748-y)
Bymaster FP, Zhang W, Carter PA et al (2002) Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology 160(4):353–361. (PMID: 1191966210.1007/s00213-001-0986-x)
Carbonaro TM, Bradstreet MP, Barrett FS et al (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol (Oxford, England) 30(12):1268–1278. (PMID: 10.1177/0269881116662634)
Carhart-Harris RL, Bolstridge M, Rucker J et al (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3(7):619–627. (PMID: 2721003110.1016/S2215-0366(16)30065-7)
Carhart-Harris RL, Bolstridge M, Day CMJ et al (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235(2):399–408. (PMID: 2911921710.1007/s00213-017-4771-x)
Casale JF (1985) An aqueous-organic extraction method for the isolation and identification of psilocin from hallucinogenic mushrooms. J Forensic Sci 30(1):247–250. (PMID: 403899210.1520/JFS10989J)
Chary M, Genes N, Giraud-Carrier C et al (2017) Epidemiology from tweets: estimating misuse of prescription opioids in the USA from social media. J Med Toxicol 13(4):278–286. (PMID: 28831738571175610.1007/s13181-017-0625-5)
Cosci F, Chouinard G (2020) Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom 89(5):283–306. (PMID: 3225982610.1159/000506868)
Culbertson VL, Rahman SE, Bosen GC et al (2018) Implications of off-target serotoninergic drug activity: an analysis of serotonin syndrome reports using a systematic bioinformatics approach. Pharmacotherapy 38(9):888–898. (PMID: 29972695616035310.1002/phar.2163)
Davis AK, Barrett FS, May DG et al (2020) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2020.3285. (PMID: 10.1001/jamapsychiatry.2020.3285319951357643046)
de la Fuente Revenga M, Jaster AM, McGinn J et al (2022) Tolerance and cross-tolerance among psychedelic and nonpsychedelic 5-HT2A receptor agonists in mice. ACS Chem Neurosci 13(16):2436–2448 (American Chemical Society). (PMID: 3590087610.1021/acschemneuro.2c00170)
de Montigny C, Chaput Y, Blier P (1990) Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. J Clin Psychiatry 51:4–8 (US: Physicians Postgraduate Press). (PMID: 2175309)
Dean B (2021) Reddit user and growth stats (Updated Oct 2021). https://backlinko.com/reddit-users . Accessed 21 Dec 2022.
Diaz SL, Maroteaux L (2011) Implication of 5-HT2B receptors in the serotonin syndrome. Neuropharmacology 61(3):495–502 (Serotonin: The New Wave). (PMID: 2127787510.1016/j.neuropharm.2011.01.025)
Dinis-Oliveira RJ (2017) Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev 49(1):84–91 (Taylor & Francis). (PMID: 2807467010.1080/03602532.2016.1278228)
dos Santos RG, Hallak JEC (2020) Therapeutic use of serotoninergic hallucinogens: a review of the evidence and of the biological and psychological mechanisms. Neurosci Biobehav Rev 108:423–434. (PMID: 3180977210.1016/j.neubiorev.2019.12.001)
dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ et al (2018) Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert Rev Clin Pharmacol 11(9):889–902. (PMID: 3010207810.1080/17512433.2018.1511424)
Dunkley EJC, Isbister GK, Sibbritt D et al (2003) The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM: Int J Med 96(9):635–642. (PMID: 10.1093/qjmed/hcg109)
Erkizia-Santamaría I, Alles-Pascual R, Horrillo I et al (2022) Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response. Biomed Pharmacother 154:113612. (PMID: 3604931310.1016/j.biopha.2022.113612)
Fiorella D, Helsley S, Rabin RA et al (1996) Potentiation of LSD-induced stimulus control by fluoxetine in the rat. Life Sci 59(18):PL283–PL287. (PMID: 889094010.1016/0024-3205(96)00490-0)
Flanagan TW, Nichols CD (2018) Psychedelics as anti-inflammatory agents. Int Rev Psychiatry 30(4):363–375. (PMID: 3010208110.1080/09540261.2018.1481827)
Fleiss JL (1971) Measuring nominal scale agreement among many raters. Psychol Bull 76:378–382 (US: American Psychological Association). (PMID: 10.1037/h0031619)
Fornaro M, Cattaneo CI, De Berardis D et al (2023) Antidepressant discontinuation syndrome: a state-of-the-art clinical review. Eur Neuropsychopharmacol 66:1–10. (PMID: 3634509310.1016/j.euroneuro.2022.10.005)
Francescangeli J, Karamchandani K, Powell M et al (2019) The serotonin syndrome: from molecular mechanisms to clinical practice. Int J Mol Sci 20(9):2288. (PMID: 31075831653956210.3390/ijms20092288)
Freedman DX, Gottlieb R, Lovell RA (1970) Psychotomimetic drugs and brain 5-hydroxytryptamine metabolism. Biochem Pharmacol 19:1181–1188. (PMID: 10.1016/0006-2952(70)90378-3)
Friesen P (2022) Psychosis and psychedelics: Historical entanglements and contemporary contrasts. Transcult Psychiatry 59(5):592–609. (PMID: 36300247966027310.1177/13634615221129116)
Galvão-Coelho NL, Marx W, Gonzalez M et al (2021) Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology. https://doi.org/10.1007/s00213-020-05719-1. (PMID: 10.1007/s00213-020-05719-1334279447826317)
Gard DE, Pleet MM, Bradley ER et al (2021) Evaluating the risk of psilocybin for the treatment of bipolar depression: a review of the research literature and published case studies. J Affect Disord Rep 6:100240. (PMID: 10.1016/j.jadr.2021.100240)
Gardier A, Malagié I, Trillat A et al (1996) Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam Clin Pharmacol 10(1):16–27. (PMID: 890049610.1111/j.1472-8206.1996.tb00145.x)
Gillman PK (2004) The spectrum concept of serotonin toxicity. Pain Med 5(2):231–232. (PMID: 1520998810.1111/j.1526-4637.2004.04033.x)
Gold CB (1991) The mushroom entheogen - The measure of the mushroom. In: Psychedelic Monographs and Essays, p. 5. http://en.psilosophy.info/the_mushroom_entheogen_the_measure_of_the_mushroom.html . Accessed 12 Jan 2023.
González-Maeso J, Sealfon SC (2009) Psychedelics and schizophrenia. Trends Neurosci 32(4):225–232. (PMID: 1926904710.1016/j.tins.2008.12.005)
Goodwin GM, Aaronson ST, Alvarez O et al (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 387(18):1637–1648 (Massachusetts Medical Society). (PMID: 3632284310.1056/NEJMoa2206443)
Goodwin GM, Croal M, Feifel D et al (2023) Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology. https://doi.org/10.1038/s41386-023-01648-7. (PMID: 10.1038/s41386-023-01648-73744338610425429)
Graves RL, Perrone J, Al-Garadi MA et al (2022) Thematic analysis of Reddit content about buprenorphine-naloxone using manual annotation and natural language processing techniques. J Addict Med 16(4):454. (PMID: 3486478810.1097/ADM.0000000000000940)
Griffiths RR, Richards WA, McCann U et al (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187(3):268–283. (PMID: 1682640010.1007/s00213-006-0457-5)
Griffiths RR, Johnson MW, Richards WA et al (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology 218(4):649–665. (PMID: 21674151330835710.1007/s00213-011-2358-5)
Griffiths RR, Johnson MW, Carducci MA et al (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol (Oxford, England) 30(12):1181–1197. (PMID: 10.1177/0269881116675513)
Gukasyan N, Griffiths R, Yaden D et al (2023) Attenuation of psilocybin mushroom effects during and after SSRI-SNRI antidepressant use. J Psychopharmacol. https://doi.org/10.1177/02698811231179910. (PMID: 10.1177/0269881123117991037291890)
Gumpper RH, Fay JF, Roth BL (2022) Molecular insights into the regulation of constitutive activity by RNA editing of 5HT2C serotonin receptors. Cell Rep 40(7):111211. (PMID: 35977511942234710.1016/j.celrep.2022.111211)
Haberzettl R, Fink H, Bert B (2014) Role of 5-HT1A- and 5-HT2A receptors for the murine model of the serotonin syndrome. J Pharmacol Toxicol Methods 70(2):129–133. (PMID: 2508775410.1016/j.vascn.2014.07.003)
Hermle L, Simon M, Ruchsow M et al (2012) Hallucinogen-persisting perception disorder. Ther Adv Psychopharmacol 2(5):199–205. (PMID: 23983976373694410.1177/2045125312451270)
Hesselgrave N, Troppoli TA, Wulff AB, Thompson SM (2021) Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci USA 118(17). https://doi.org/10.1073/pnas.2022489118.
Hibicke M, Landry AN, Kramer HM, Talman ZK, Nichols CD (2020) Psychedelics but not ketamine produce persistent antidepressant-like effects in a rodent experimental system for the study of depression. ACS Chem Neurosci 11(6):864–871. https://doi.org/10.1021/acschemneuro.9b00493.
Hsieh H-F, Shannon SE (2005) Three approaches to qualitative content analysis. Qual Health Res 15(9):1277–1288. (PMID: 1620440510.1177/1049732305276687)
Johnson M, Richards W, Griffiths R (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol (Oxford, England) 22(6):603–620. (PMID: 10.1177/0269881108093587)
Johnson MW, Garcia-Romeu A, Cosimano MP et al (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28(11):983–992. (PMID: 25213996428632010.1177/0269881114548296)
Kakiuchi T, Tsukada H, Fukumoto D et al (2001) Effects of aging on serotonin transporter availability and its response to fluvoxamine in the living brain: PET study with [11C](+)McN5652 and [11C] (-)McN5652 in conscious monkeys. Synapse 40(3):170–179. (PMID: 1130475410.1002/syn.1039)
Kitaichi Y, Inoue T, Nakagawa S et al (2010) Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur J Pharmacol 647(1):90–96. (PMID: 2081681410.1016/j.ejphar.2010.08.026)
Klimek V, Zak-Knapik J, Mackowiak M (1994) Effects of repeated treatment with fluoxetine and citalopram, 5-HT uptake inhibitors, on 5-HT1A and 5-HT2 receptors in the rat brain. J Psychiatry Neurosci: JPN 19(1):63–67. (PMID: 81483681188564)
Ko K, Kopra EI, Cleare AJ et al (2023) Psychedelic therapy for depressive symptoms: a systematic review and meta-analysis. J Affect Disord 322:194–204. (PMID: 3620978010.1016/j.jad.2022.09.168)
Kolb P, Kenakin T, Alexander SPH et al (2022) Community guidelines for GPCR ligand bias: IUPHAR review 32. Br J Pharmacol 179(14):3651–3674. (PMID: 3510675210.1111/bph.15811)
Kopra EI, Ferris JA, Winstock AR et al (2023) Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020. J Psychopharmacol 37(7):733–748 (SAGE Publications Ltd STM: 02698811231158245). (PMID: 368765831035072710.1177/02698811231158245)
Kozell LB, Eshleman AJ, Swanson TL et al (2023) Pharmacologic activity of substituted tryptamines at 5-Hydroxytryptamine (5-HT) 2A receptor (5-HT 2A R), 5-HT 2C R, 5-HT 1A R, and serotonin transporter. J Pharmacol Exp Ther 385(1):62–75. (PMID: 366698751002982210.1124/jpet.122.001454)
Langley C, Armand S, Luo Q et al (2023) Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study. Neuropsychopharmacology 48(4):664–670. (PMID: 36683090993811310.1038/s41386-022-01523-x)
Leger RF, Unterwald EM (2022) Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: a systematic review and meta-analysis. J Psychopharmacol 36(1):20–30. (PMID: 3451956710.1177/02698811211044688)
Leonard JB, Anderson B, Klein-Schwartz W (2018) Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. J Psychopharmacol 32(12):1286–1294 (SAGE Publications Ltd STM). (PMID: 3018279510.1177/0269881118793086)
Litjens RPW, Brunt TM, Alderliefste G-J et al (2014) Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol 24(8):1309–1323. (PMID: 10.1016/j.euroneuro.2014.05.008)
Lou J-S (2020) Chapter Nine - Placebo responses in Parkinson’s disease. In: Witek NP, Goetz CG, Stebbins GT (eds) International Review of Neurobiology. Placebo Effects in Neurologic Disease. Academic Press, pp 187–211. https://www.sciencedirect.com/science/article/pii/S0074774220300623 . Accessed 3 Oct 2022.
Ly C, Greb AC, Cameron LP et al (2018) Psychedelics promote structural and functional neural plasticity. Cell Rep 23(11):3170–3182. (PMID: 29898390608237610.1016/j.celrep.2018.05.022)
Madsen MK, Fisher PM, Burmester D et al (2019) Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 44(7):1328–1334. (PMID: 30685771678502810.1038/s41386-019-0324-9)
Malcolm B, Thomas K (2021) Serotonin toxicity of serotonergic psychedelics. Psychopharmacology. https://doi.org/10.1007/s00213-021-05876-x. (PMID: 10.1007/s00213-021-05876-x34251464)
Marazziti D, Mucci F, Tripodi B et al (2019) Emotional blunting, cognitive impairment, bone fractures, and bleeding as possible side effects of long-term use of SSRIs. Clin Neuropsychiatry 16(2):75–85. (PMID: 349089418650205)
Markel H, Lee A, Holmes RD et al (1994) LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents. J Pediatr 125(5, Part 1):817–819. (PMID: 796544010.1016/S0022-3476(06)80189-7)
Massou JM, Trichard C, Attar-Levy D et al (1997) Frontal 5-HT 2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors. Psychopharmacology 133(1):99–101. (PMID: 933508710.1007/s002130050377)
Mazzola-Pomietto P, Aulakh CS, Wozniak KM et al (1995) Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors. Psychopharmacology 117(2):193–199. (PMID: 775396710.1007/BF02245187)
Messa C, Colombo C, Moresco RM et al (2003) 5-HT2A receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology 167(1):72–78. (PMID: 1263224610.1007/s00213-002-1379-5)
Meyer JH, Kapur S, Eisfeld B et al (2001) The effect of paroxetine on 5-HT2A receptors in depression: an [18F]Setoperone PET imaging study. Am J Psychiatry 158(1):78–85 (American Psychiatric Publishing). (PMID: 1113663710.1176/appi.ajp.158.1.78)
Meyer JH, Wilson AA, Sagrati S et al (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161(5):826–835 (American Psychiatric Publishing). (PMID: 1512164710.1176/appi.ajp.161.5.826)
Mody I, MacDonald JF (1995) NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release. Trends Pharmacol Sci 16(10):356–359. (PMID: 749171410.1016/S0165-6147(00)89070-7)
Moliner R, Girych M, Brunello CA et al (2023) Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci 26(6):1032–1041 (Nature Publishing Group). (PMID: 372803971024416910.1038/s41593-023-01316-5)
Moreno FA, Wiegand CB, Taitano EK et al (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67(11):1735–1740. (PMID: 1719605310.4088/JCP.v67n1110)
Morton E, Sakai K, Ashtari A, Pleet M, Michalak EE, Woolley J (2022) Risks and benefits of psilocybin use in people with bipolar disorder: an international web-based survey on experiences of ‘magic mushroom’ consumption. J Psychopharmacol 37(1):49–60. https://doi.org/10.1177/02698811221131997 ‌.
Moses-Kolko EL, Price JC, Shah N et al (2011) Age, sex, and reproductive hormone effects on brain Serotonin-1A and Serotonin-2A receptor binding in a healthy population. Neuropsychopharmacology 36(13):2729–2740. (PMID: 21849982323049610.1038/npp.2011.163)
Nardou R, Sawyer E, Song YJ et al (2023) Psychedelics reopen the social reward learning critical period. Nature Publishing Group, Nature pp 1–9.
Nayak SM, Gukasyan N, Barrett FS et al (2021) Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports. Pharmacopsychiatry 54(5):240–245 (Georg Thieme Verlag KG). (PMID: 3434841310.1055/a-1524-2794)
Nelson BK, Brightwell WS, Robertson SK et al (1989) Behavioral teratology investigation of 1-butanol in rats. Neurotoxicol Teratol 11(3):313–315. (PMID: 256916310.1016/0892-0362(89)90074-3)
Nichols DE (2004) Hallucinogens. Pharmacol Ther 101(2):131–181. (PMID: 1476170310.1016/j.pharmthera.2003.11.002)
Nichols DE (2016) Psychedelics. Pharmacol Rev 68(2):264–355. (PMID: 26841800481342510.1124/pr.115.011478)
Nichols DE, Walter H (2021) The history of psychedelics in psychiatry. Pharmacopsychiatry 54(04):151–166. (PMID: 3328557910.1055/a-1310-3990)
Nikiforuk A (2015) Targeting the serotonin 5-HT7 receptor in the search for treatments for CNS disorders: rationale and progress to date. CNS Drugs 29(4):265–275. (PMID: 25721336455534310.1007/s40263-015-0236-0)
Nisijima K, Yoshino T, Yui K et al (2001) Potent serotonin (5-HT)2A receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res 890(1):23–31. (PMID: 1116476510.1016/S0006-8993(00)03020-1)
Olson DE (2020) The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. https://doi.org/10.1021/acsptsci.0c00192 . (American Chemical Society). (PMID: 10.1021/acsptsci.0c00192338612188033607)
Pokorny T, Preller KH, Kraehenmann R et al (2016) Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol 26(4):756–766. (PMID: 2687511410.1016/j.euroneuro.2016.01.005)
Prakash S, Belani P, Trivedi A (2014) Headache as a presenting feature in patients with serotonin syndrome: a case series. Cephalalgia 34(2):148–153. (PMID: 2382798110.1177/0333102413495968)
Prakash S, Rathore C, Rana K et al (2021) Fatal serotonin syndrome: a systematic review of 56 cases in the literature. Clin Toxicol 59(2):89–100 (Taylor & Francis). (PMID: 10.1080/15563650.2020.1839662)
Preller KH, Duerler P, Burt JB et al (2020) Psilocybin induces time-dependent changes in global functional connectivity. Biol Psychiatry 88(2):197–207 (Elsevier). (PMID: 3211134310.1016/j.biopsych.2019.12.027)
Price J, Cole V, Goodwin GM (2009) Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry 195(3):211–217. (PMID: 1972110910.1192/bjp.bp.108.051110)
Radhakrishnan R, Nabulsi N, Gaiser E et al (2018) Age-related change in 5-HT 6 receptor availability in healthy male volunteers measured with ¹¹ C-GSK215083 PET. J Nucl Med 59(9):1445–1450. (PMID: 29626125612643710.2967/jnumed.117.206516)
Renoir T (2013) Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. Front Pharmacol 4:45. (PMID: 23596418362713010.3389/fphar.2013.00045)
Rhidenour KB, Blackburn K, Barrett AK et al (2022) Mediating medical marijuana: exploring how veterans discuss their stigmatized substance use on Reddit. Health Commun 37(10):1305–1315. (PMID: 3360200010.1080/10410236.2021.1886411)
Rickli A, Moning OD, Hoener MC et al (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol 26(8):1327–1337. (PMID: 10.1016/j.euroneuro.2016.05.001)
Romeo B, Karila L, Martelli C et al (2020) Efficacy of psychedelic treatments on depressive symptoms: a meta-analysis. J Psychopharmacol 34(10):1079–1085 (SAGE Publications Ltd STM). (PMID: 3244804810.1177/0269881120919957)
Rotz R von, Schindowski EM, Jungwirth J et al (2023) Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, Elsevier, p 56.
Safarishahrbijari A, Osgood N (2018) Social media surveillance improves outbreak projection via transmission models (preprint).
Schindler EAD (2022) Psychedelics as preventive treatment in headache and chronic pain disorders. Neuropharmacology 215:109166. (PMID: 3571800510.1016/j.neuropharm.2022.109166)
Schindler EAD, Sewell RA, Gottschalk CH et al (2021) Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurotherapeutics 18(1):534–543. (PMID: 3318474310.1007/s13311-020-00962-y)
Shao L-X, Liao C, Gregg I et al (2021) Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 109(16):2535-2544.e4. (PMID: 34228959837677210.1016/j.neuron.2021.06.008)
Shelton JT, Elliott EM, Hill BD et al (2009) A comparison of laboratory and clinical working memory tests and their prediction of fluid intelligence. Intelligence 37(3):283–293. (PMID: 20161647281830410.1016/j.intell.2008.11.005)
Stahl SM (1998) Mechanism of action of serotonin selective reuptake inhibitors: Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51(3):215–235. (PMID: 1033397910.1016/S0165-0327(98)00221-3)
Steinberg LJ, Underwood MD, Bakalian MJ et al (2019) 5-HT 1A receptor, 5-HT 2A receptor and serotonin transporter binding in the human auditory cortex in depression. J Psychiatry Neurosci 44(5):294–302. (PMID: 31120232671008610.1503/jpn.180190)
Stenbæk DS, Madsen MK, Ozenne B et al (2021) Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. J Psychopharmacol 35(4):459–468 (SAGE Publications Ltd STM). (PMID: 3350185710.1177/0269881120959609)
Studerus E, Gamma A, Vollenweider FX (2010) Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV). PLOS ONE 5(8):e12412. (PMID: 20824211293085110.1371/journal.pone.0012412)
Studerus E, Gamma A, Kometer M et al (2012) Prediction of psilocybin response in healthy volunteers. PLOS ONE 7(2):e30800. (PMID: 22363492328187110.1371/journal.pone.0030800)
Suzuki K (2016) Three cases of acute serotonin syndrome due to psilocybin mushroom poisoning. 29(1):33–35.
Tamam L, Ozpoyraz N (2002) Selective serotonin reuptake inhibitor discontinuation syndrome: a review. Adv Ther 19:17–26. (PMID: 1200885810.1007/BF02850015)
Tiscione NB, Miller MI (2006) Psilocin identified in a DUID investigation. J Anal Toxicol 30(5):342–345. (PMID: 1683947310.1093/jat/30.5.342)
Tohen M, Frank E, Bowden CL et al (2009) The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 11(5):453–473. (PMID: 1962438510.1111/j.1399-5618.2009.00726.x)
Vaismoradi M, Jones J, Turunen H et al (2016) Theme development in qualitative content analysis and thematic analysis. J Nurs Educ Pract 6(5):100.
Versijpt J, Van Laere KJ, Dumont F et al (2003) Imaging of the 5-HT2A system: age-, gender-, and Alzheimer’s disease-related findings. Neurobiol Aging 24(4):553–561. (PMID: 1271411210.1016/S0197-4580(02)00137-9)
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A et al (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9(17):3897–3902. (PMID: 987572510.1097/00001756-199812010-00024)
Wojtas A, Bysiek A, Wawrzczak-Bargiela A et al (2022) Effect of psilocybin and ketamine on brain neurotransmitters, glutamate receptors, DNA and rat behavior. Int J Mol Sci 23(12):6713. (PMID: 35743159922448910.3390/ijms23126713)
Yockey A, King K (2021) Use of psilocybin (“mushrooms”) among US adults: 2015–2018. J Psychedelic Stud 5(1):17–21 (Akadémiai Kiadó). (PMID: 10.1556/2054.2020.00159)
Zhou L, Bohn LM (2014) Functional selectivity of GPCR signaling in animals. Curr Opin Cell Biol 27:102–108. (PMID: 2468043510.1016/j.ceb.2013.11.010)

Keywords: Antidepressant; Drug-drug interactions; Psilocybin; Serotonin

2RV7212BP0 (Psilocybin)
0 (Selective Serotonin Reuptake Inhibitors)
0 (Hallucinogens)

Date Created: 20240430 Date Completed: 20240724 Latest Revision: 20240724

20240726

10.1007/s00213-024-06585-x

38687360